Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients

American Journal of Transplantation

Volumn 13, Issue 12, 2013, Pages 3155-3163

  Silva, H T ^a   Felipe, C R ^a   Garcia, V D ^b   Neto, E D ^c   Filho, M A ^d   Contieri, F L C ^e   De Carvalho, D D B M ^f   Pestana, J O M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Santa Casa de Misericordia de Goiania   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^e HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^f HOSPITAL GERAL DE BONSUCESSO   (Brazil)

Author keywords

Conversion; Kidney transplantation; Sirolimus; Tacrolimus

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENTION TO TREAT ANALYSIS; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCORING SYSTEM; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ZYGOMYCOSIS;

CONVERSION; KIDNEY TRANSPLANTATION; SIROLIMUS; TACROLIMUS;

ADULT; BIOPSY; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84888371502     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12481     Document Type: Article

References (21)

1. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
3. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252.
4. Knight RJ, Kahan BD., The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity ? Kidney Int 2006; 70: 994-999.
5. Cravedi P, Ruggenenti P, Remuzzi G., Sirolimus for calcineurin inhibitors in organ transplantation: Contra. Kidney Int 2010; 78: 1068-1074.
6. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
7. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
8. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
9. Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K., Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: Results of a pilot study. Clin Transplant 2008; 22: 366-371.
10. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744-2753.
11. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
12. Lebranchu Y, Snanoudj R, Toupance O, et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: The SPIESSER study. Am J Transplant 2012; 12: 1801-1810.
13. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175-183.
14. Holdaas H, Rostaing L, Serõn D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.
15. Di Marco GS, de Andrade MC, Felipe CR, et al. Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2003; 25: 558-564.
16. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
17. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
18. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. Am J Transplant 2012; 12: 2446-2456.
19. Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012; 12: 1528-1540.
20. Cortazar F, Molnar MZ, Isakova T, et al. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2012; 12: 379-387.
21. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU., Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586-594.